Compare Incyte Corporation (INCY) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Raymond James Financial, Inc. — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Raymond James Financial, Inc. trades at $168.25 (market cap $32.80B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | RJF | |
|---|---|---|
Market Cap | $23.11B | $32.80B |
Sector | Health | Financials |
52-Week High | $118.52 | $176.43 |
52-Week Low | $67.38 | $140.89 |
Enterprise Value | $19.13B | — |
Dividend Yield | — | 1.28% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
